Drug intelligence / Profile preview

JNP-0101

Development stage: Unknown
Lead developer: Daré Bioscience
Modality: Small Molecules
Administration: Intravaginal

Overview

**JNP-0101** is an investigational intravaginal ring (IVR) formulation of oxybutynin, an antimuscarinic agent that decreases bladder muscle spasms to treat overactive bladder (OAB) in women. Developed using proprietary multi-segment IVR technology, it enables localized absorption via shared vascular and lymphatic networks of the vagina and bladder, aiming to achieve higher concentrations in target tissues while minimizing systemic side effects and hepatic first-pass metabolism compared to oral oxybutynin.[1][3][7]

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on JNP-0101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNP-0101.

Explore the full profile